KinCon biolabs created a unique biological reporter platform that revolutionizes the way we track cellular reactions. The underlying cell-based technology monitors alterations of direct drug-induced changes in target-protein activity conformations in a high-content-format, which is challenging to obtain with traditional methods. KinCon biolabs provides a window into the functioning of drug-candidates at the cellular level, offering valuable insights into both efficacy and mechanisms of action. By enhancing the validation process of drug-candidates it accelerates and empowers early-stage drug development. With its expanding reporter platform, KinCon reporters enable the identification of effective drugs for the hard-to-target proteins.